For how we live.
A 585-nodule series found a RAS mutation on biopsy is a weak cancer signal on its own, and that isolated-RAS cancers almost never recurred — evidence that could spare some patients a total thyroidectomy.
Across 1463 patients at 49 centres, 13% died of Cushing-related causes and 43% died overall. Reaching biochemical remission within six months roughly halved the risk of those deaths.
Insulin icodec, cleared for adults in March, gained a paediatric indication on 23 October for patients 10 and older with type 2 diabetes. The FDA relied on adult trial data plus a paediatric pharmacokinetic study.
In the REAL8 phase 3 trial, children born small for gestational age kept growing on weekly somapacitan — including those switched from daily injections — with most preferring the weekly shot.
Satralizumab, cleared on 15 October, is the first interleukin-6 receptor blocker approved for the eye-bulging autoimmune disease. One of its two identical trials hit the main goal; the other missed it.
In 4,299 people with type 1 diabetes and 17,196 matched controls, the death rate was 131 vs 35 per 100,000 person-years. The excess risk was far larger in women, though absolute mortality was higher in men.
A 96,000-woman registry emulation found pre-conception GLP-1 or GLP-1/GIP therapy in PCOS tracked with lower pregnancy risk than metformin. It is not a trial, and says nothing about use during pregnancy.
A single-centre study used continuous glucose monitoring to fine-tune insulin in people fed intravenously overnight. Time-in-range and weight improved — but with 12 patients and no control group, it is proof of concept.
One lot of Vitruvias's 1/2-grain Thyroid Tablets — 1,955 bottles sold nationwide — was pulled after testing showed the tablets carry more hormone than the label states. The FDA calls it its most serious recall class.
In the phase 3 THRIVE trial, veligrotug shrank bulging eyes in 70% of patients versus 5% on placebo. It is the first serious challenger to the only drug approved for the condition.
Satralizumab reduced eye-bulging and inflammation in thyroid eye disease across the twin SatraGO phase 3 trials, but the primary proptosis endpoint reached statistical significance in only one of them.
Two datasets report an age-independent fall in men's testosterone across birth cohorts. A separate study of nine thousand men found much of the variation between cohorts came from the tests themselves.
Oral paltusotine kept median IGF-I near the normal ceiling through week 207 in an open-label extension, but only 20 of 43 patients remained by then and the study had no comparison group.
Palsonify is cleared for adults whose acromegaly did not respond adequately to surgery. In the phase 3 switching trial, 83.3% on the pill kept biochemical control versus 3.6% on placebo.